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Uromodulin (UMOD) mutations are responsible for three autosomal dominant tubulo-interstitial nephropa-
thies including medullary cystic kidney disease type 2 (MCKD2), familial juvenile hyperuricemic nephropathy
and glomerulocystic kidney disease. Symptoms include renal salt wasting, hyperuricemia, gout, hyperten-
sion and end-stage renal disease. MCKD is part of the ‘nephronophthisis–MCKD complex’, a group of
cystic kidney diseases. Both disorders have an indistinguishable histology and renal cysts are observed
in either. For most genes mutated in cystic kidney disease, their proteins are expressed in the primary
cilia/basal body complex. We identified seven novel UMOD mutations and were interested if UMOD protein
was expressed in the primary renal cilia of human renal biopsies and if mutant UMOD would show a different
expression pattern compared with that seen in control individuals. We demonstrate that UMOD is expressed
in the primary cilia of renal tubules, using immunofluorescent studies in human kidney biopsy samples. The
number of UMOD-positive primary cilia in UMOD patients is significantly decreased when compared with con-
trol samples. Additional immunofluorescence studies confirm ciliary expression of UMOD in cell culture.
Ciliary expression of UMOD is also confirmed by electron microscopy. UMOD localization at the mitotic spin-
dle poles and colocalization with other ciliary proteins such as nephrocystin-1 and kinesin family member 3A
is demonstrated. Our data add UMOD to the group of proteins expressed in primary cilia, where mutations of
the gene lead to cystic kidney disease.
INTRODUCTION
Uromodulin (UMOD) mutations have been reported in three
autosomal dominant tubulo-interstitial nephropathies: (i)
medullary cystic kidney disease (MCKD2) (OMIM 603860),
(ii) familial juvenile hyperuricemic nephropathy (FJHN)
(OMIM 162000) and (iii) in glomerulocystic kidney disease
(GCKD) (OMIM 609886) (1–3).
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UMOD mutations result in a urinary concentration defect,
urinary salt wasting, hyperuricemia, gout, hypertension and
end-stage renal disease (ESRD). MCKD2 is characterized by
hypertension and ESRD in the fourth decade of life. Renal
ultrasound in affected patients may show small cortico-
medullary cysts. MCKD2 shows a renal histologic triad of
(1) tubular basement membrane disintegration (2), tubular
atrophy with cyst development at the corticomedullary
border and (3) interstitial cell infiltration associated with fibro-
sis. The condition shares clinical and morphological simi-
larities with autosomal recessive juvenile nephronophthisis
(NPHP) (4,5). In contrast to juvenile onset of ESRD and the
autosomal-recessive inheritance in NPHP, MCKD2 leads to
ESRD in adulthood and is inherited in an autosomal-dominant
pattern (6). FJHN may present with hyperuricemia in child-
hood and early adult life (7). GCKD is characterized by a
cystic dilatation of Bowman’s space and a collapse of the glo-
merular tuft. Familial GCKD can be associated with hypoplas-
tic kidneys (3). All three disorders show significant clinical
overlap. Characteristics of both FJHN and MCKD2 were
described in one kindred (8). Another group published 10 kin-
dreds with UMOD mutations and FJHN. Five of the 10 kin-
dreds had renal cysts and even within the same family there
was variation with regard to the presence of cysts (2).
Because all three phenotypes can be caused by the same
UMOD mutation, these three disorders (FJHN, MCKD2 and
GCKD) have also been described as ‘Uromodulin-associated
kidney disease’ (UAKD) (9,10).
The UMOD gene encodes the Uromodulin (UMOD) protein
(alias Tamm-Horsfall protein) and contains three epidermal
growth factor-like (EGF-like) domains, a cysteine-rich D8C
domain, and a zona pellucida domain. Forty-six different mis-
sense mutations in the UMOD gene have been described (1–
3,11,12). For MCKD2, FJHN and GCKD patients, decreased
urinary UMOD excretion and retention of the misfolded
UMOD in the endoplasmatic reticulum (ER) is a postulated
mechanism of disease (2,3,12). The mutant UMOD protein
showed delayed ER to Golgi trafficking (12,13) as a result
of an altered protein conformation and leading to an increased
rate of apoptosis (14).
UMOD represents the most abundant urinary protein in
humans (15). UMOD is expressed in renal tubular cells primar-
ily at the apical surface of the thick ascending loop of Henle
(TAL) and of the early distal convoluted tubules. It is a trans-
membrane protein, which is secreted into the urine through pro-
teolytic cleavage of the glycosylphosphatidylinositol (GPI)
anchor (16). UMOD is an 80–90 kDa macromolecule, which
has been shown to be involved as a protective factor in
urinary tract infections (UTI), in binding of complement
factors and immunoglobulin light chains (to form casts in
myeloma kidney), and as an inhibitor of nephrolithiasis (17–
22). AnUmod knock-out mouse model underlines the protective
effects of UMOD in UTI caused by fimbriated Escherichia coli
(23). Another mouse model (UMODA227T) shows that homozy-
gous mice have a very similar phenotype to human UAKD with
azotemia, impaired urine concentration and reduced urinary
excretion of uric acid (24). In addition, a recent genome-wide
association study found a significant single nucleotide poly-
morphism association of the UMOD locus with chronic
kidney disease (25). Different modifications of the UMOD
protein by N- and O-linked glycosylation have been described
(26), and are responsible for interactions with interleukin-1,
tumor necrosis factor-a, immunoglobulin light chains, IgG,
complement 1 and 1q (20,21,27–29). Moreover stimulation of
polymorphonuclear neutrophils, lymphocytes and monocytes
by UMOD was shown (30–32). UMOD can directly activate
dendritic cells via the Toll-like receptor 4 pathway, indicating
a role in the innate immune response (33). In addition, the
ability of UMOD to polymerize in vitro and so forming a
gel-like structure has resulted in the hypothesis that UMOD is
important for the water impermeability of the TAL (34).
Recently, ciliary expression of multiple ‘cystoproteins’,
which are responsible for cystic kidney disease if altered,
has been demonstrated (35). Expression in renal primary
cilia was shown for: (i) polycystin-1 and -2, encoded by
PKD1 and PKD2, where mutations lead to autosomal-
dominant polycystic kidney disease (ADPKD) (36); (ii) fibro-
cystin/polyductin, encoded by PKHD1, where mutations lead
to autosomal-recessive polycystic kidney disease (ARPKD)
(37); and (iii) the nephrocystin-1 to -11, proteins, where
mutations in the genes NPHP1-11 cause nephronophthisis
(NPHP) (6). Ciliary and basal body expression was also
shown for the protein products of Bardet–Biedl syndrome
(BBS) genes. Patients with BBS and NPHP often share pheno-
types (38). Ciliary expression has also been shown for the gene
products of a number of cystic kidney knock-out mouse
models implicating a role in the primary cilia for polaris,
cystin, inversin and NEK8 (39–42). In addition, the transcrip-
tion factor HNF1B was identified as an upstream regulator of
nephrocystins and UMOD (43). In this report we describe
seven novel mutations in the UMOD gene. Because of the pre-
vious hypothesis of the ‘MCKD—nephronophthisis’ complex,
similar histopathological findings and the regulation of both
genes by HNF1B, we were interested in studying: (i) if
UMOD would be expressed in renal primary cilia, (ii) if
mutant UMOD would show a different expression pattern
and subcellular localization in human renal biopsies and (iii)
if UMOD could be linked to the ciliary hypothesis of
cystogenesis.
RESULTS
Mutation analysis
We performed mutational analysis in 54 individuals compati-
ble with UAKD from 44 different unrelated kindreds. Out of
the 54 individuals, 17 patients presented with familial
disease in seven kindreds. Affected individuals underwent
mutation analysis by exon polymerase chain reaction (PCR)
and direct sequencing of all UMOD exons. We identified
seven novel mutations in 11 individuals of seven kindreds:
c.172 G . T (p.G58C); c.206G . A (p.C69Y); c.317G . A
(p.C106Y); c.448T . A (p.C150S); c.688T . C (p.W230R);
c.743G . C (p.C248S); c.821A . G (p.Y274C) (Table 1). In
addition, we identified three previously published mutations
in three individuals: 383del12/ins9 VCPEG93-97AASC;
c.586G . A (p.D196N); c.898T . G (p.C300G) (Table 1).
A cysteine residue was substituted by another amino acid in
four of the seven novel UMOD mutations and in two of the
previously known mutations. In two of the seven novel
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UMOD mutations another amino acid was changed to a
cysteine. None of the mutations were found in 100 healthy
Caucasian controls, indicating that our detected mutations
are unlikely to be common polymorphisms and are most
likely disease-causing. Moreover, the PolyPhen software
(http://genetics.bwh.harvard.edu/pph/index.html) predicted all
Table 1. Summary of the identified UMOD mutations and corresponding patients’ characteristics
Individual Age at
onset
(years)
S. Cr.
(mg/
dl)
GFR (ml/
min/
1.73 m2)
S. UA.
(mg/dl)
Clinical
characteristics
Ultrasound/biopsy
findings
Mutation/
(amino acid
change)
PolyPhen
PSIC score
differencea
Affected
UMOD
domain
F1
II-1 13 25.3 3 n.d. anemia, ESRD, HTN,
HD, proteinuria
US:  echogenicity,
renal atrophy, cysts
c.172 G. T
(G58C)
2.397 EGF-like
domain 1
II-2 12 3.3 23 n.d. anemia US:  echogenicity,
cysts, Bx: TIF, cysts,
TA
c.172 G. T
(G58C)
2.397 EGF-like
domain 1
F2
III-1 43 n.d. n.d. n.d. ESRD, positive FHxb Bx: sister with Bx c.206G. A
(C69Y)
3.084 EGF-like
domain 2
F8
II-1 49 2.8 n.d. n.d. HTN, ESRD, positive
FHxc
Bx: TA, LPI, interstitial
scarring
383del12/ins9
(VCPEG93-
97AASC)d
EGF-like
domain 2
F3
II-1 50 n.d. n.d. n.d. positive FHxe MRI: brother with renal
cysts and S.Cr. of
1.5
c.317G. A
(C106Y)
3.185 EGF-like
domain 2
F4
I-1 27 2.0 61 7.0 HTN, anemia,
hyperuricemia
US: nl, Bx: TA, LPI,
TIF
c.448T. A
(C150S)f
2.505 Cysteine-rich
domain
II-1 23 n.d. n.d. n.d. HTN, HD, NTX
hyperuricemia
US: small atrophic
kidneys B/L
c.448T. A
(C150S)f
2.505 Cysteine-rich
domain
F9
II-1 n.d. n.d. n.d. n.d. n.d. n.d. c.586G. A
(D196N)d
Cysteine-rich
domain
F5
II-1 36 2.5 37.5 12.6 gout, HTN, nocturia,
positive FHxg
Bx: chronic interstitial
nephritis
c.688T. C
(W230R)
3.902 D8C
F6
I-1 25 n.d. n.d. n.d. CHF, HTN, ESRD,
HD, gout, GI bleed,
varices, aortic
aneurysm
Bx: TA,TIF, thickened
basement membrane
c.743G. C
(C248S)h
3.121 D8C
II-1 18 1.5 53 9.2 anemia, HTN c.743G. C
(C248S)h
3.121 D8C
II-2 18 2.2 58 n.d. HTN, gout c.743G. C
(C248S)h
3.121 D8C
F7
II-1 13 1.5 60 3.0 HTN,
microhematuria,
hearing,
impairment, MR,
positive FHxi
Bx: glomerulosclerosis,
TA
c.821A. G
(Y274C)
2.758 D8C
F10
II-1 33 1.4 39.4 8.2 HTN, positive FHxi n.d. c.898T. G
(C300G)d
D8C
B/L, bilateral; Bx: biopsy; CHF, congestive heart failure; ESRD, end-stage renal disease; GFR, glomerular filtration rate; HD, hemodialysis; HTN, hypertension;
LPI, lympho-plasmacellular infiltrate; MR, mental retardation; MRI, magnetic resonance imaging; n.d., no data; nl, normal; NTX, renal transplant; S. Cr, serum
creatinine; S. UA., serum uric acid; TA, tubular atrophy; TIF, tubulo-interstitial fibrosis; US, ultrasound.
aPolyPhen at http://genetics.bwh.harvard.edu/pph/index.html.
bFHx: The patient’s mother (at the age of 54 years) and grandfather deceased because of ESRD. The patient’s 1 year younger brother is treated with HD. The
patient’s 6 years younger sister has an elevated S.Cr. of 1.7 mg/dl. A renal US showed medullary cysts and increased echogenicity in her kidneys. A renal biopsy
showed TIF, TA and nephrosclerosis.
cFHx: The patient’s brother, paternal grandfather and uncle have a history of ESRD.
dPreviously published mutation.
eFHx: A brother of the patient had an elevated serum creatinin of 1.5 mg/dl and an MRI showed bilateral renal cysts. The father of both patients required
hemodialysis. DNA was only available from II-1.
fThe same amino acid has been found previously affected by a c.449G. C (C150S) mutation (3).
gFHx: A sister has ESRD and gout. The patient’s father died with advanced ESRD. No DNA was available from the father or the sister.
hThe same amino acid has been found previously affected by a c.744C. G (C248W) mutation (10).
iFHx: Two brothers and a grandmother have been reported as affected. No DNA was available from these individuals.
jFHx: The patient’s paternal grandmother and father suffer from ESRD. The father has also hypertension and gout.
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new mutations as probably damaging with significant position-
specific independent counts (PSIC) score differences
(Table 1). Mutations are mostly located in the EGF-like
domains and the D8C domain.
Characterization of the UMOD mouse antibody in western
blot and immunofluorescence staining of cell cultures
Prior to analysis of human kidney biopsies and cell cultures for
possible primary cilia expression of UMOD, we characterized
a primary UMOD antibody using western blots on cell lysates
of IMCD3 cells. Lysates were separated on an 8% sodium
dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis
(PAGE) and after electrotransfer, the membranes were
probed with the mouse monoclonal antibody directed against
UMOD. The IMCD3 lysates from different time points
(Fig. 1, lanes 1 and 2) were compared with UMOD purified
from urine (Fig. 1, lane 3, U). In cell lysates of post-confluent
IMCD3 cells (which express primary cilia) grown for further 2
weeks, a clear band was detected by the UMOD antibody. This
band had a molecular weight of 80 kDa as expected and
migrated as the urinary UMOD. Staining of IMCD3 cells
with the mouse antibody showed staining of the cytoplasm
and the cilia. Primary cilia were visualized using an antibody
directed against acetylated tubulin (Supplementary Material,
Fig. S1). Pre-incubation of the antibodies with purified
UMOD only reduced the staining for UMOD significantly
but not for acetylated tubulin, thereby confirming specifity
of the antibodies (Supplementary Material, Fig. S1).
In order to rule out any non-specific staining of the UMOD
antibody to the cell surface or primary cilia, we treated
IMCD3 cells with commercially available UMOD (up to
50 mg/ml) and repeated the UMOD antibody staining. No arti-
ficially increased UMOD staining was seen after the pre-
incubation of cells with UMOD, indicating that the washing
steps during the fixation and staining would remove non-
specifically bound UMOD (data not shown). This experiment
strongly suggests that the staining in renal tubules results from
the expression of tubular cells rather than from urinary-free
UMOD sticking non-specifically to the tubular surface.
Decreased UMOD expression in primary renal cilia
of UMOD patients in human renal biopsies
In order to investigate the hypothesis that UAKD belongs to
the group of diseases termed ciliopathies, we wanted to
compare the number of UMOD-positive cilia in renal biopsy
tissue from patients with known UMOD mutations versus
control patient tissue.
In control experiments, we analyzed healthy renal biopsy
tissue from four unaffected individuals for UMOD expression.
We detected UMOD staining in ciliary structures pointing
towards the tubular lumen (Fig. 2A). Co-staining with anti-
bodies against acetylated tubulin confirmed that these struc-
tures are primary cilia (Fig. 2B). Two renal biopsies from
patients with UMOD mutations were analyzed in detail. We
anticipated a low number of patient biopsies, because a renal
biopsy is not necessarily required for diagnosing UAKD.
Patient K11 (Fig. 2C and D) was diagnosed with a
c.744C. G (C248W) mutation and her clinical characteristics
have been extensively characterized (10). In summary, patient
K11 is a female, who presented at the age of 46 years with a
serum creatinine of 1.5 mg/dl, a glomerular filtration rate
(GFR) of 58 ml/min/1.73 m2 and a serum uric acid of
5.4 mg/dl. In addition, she had mild proteinuria and hyperten-
sion. A renal ultrasound showed four to five renal cysts bilat-
erally. A kidney biopsy revealed tubulo-interstitial sclerosis,
fibrosis with interstitial lymphocytic cell infiltration, atrophic
tubuli and a thickened basement membrane. After 6 years
she required peritoneal dialysis. Patient F5 (Fig. 2E and F)
was diagnosed with a novel c.688T. C (W230R) mutation,
which was not present in 190 control individuals (Table 1).
In order to rule out an unspecific effect reducing the ciliary
UMOD staining owing to tubulo-interstitial kidney disease,
we analyzed three kidney biopsies of patients with other
tubulo-intersitial kidney diseases (Supplementary Material,
Fig. S2). The three patients (C1–C3) were diagnosed with
primary hyperoxaluria (C1) and interstitial nephritis (C2 and
C3). In each renal biopsy specimen 20 tubules of the TAL,
identified by intense UMOD staining, were analyzed for
numbers of cilia and UMOD-positive cilia. In both of the
UMOD patients’ renal biopsies, we found a reduction in the
total number of cilia in the TAL when compared with
control samples (24 and 17 in 20 tubuli in each UMOD
patient compared with the mean value of 44 in each of the
four healthy control samples and 51 in each of the three
patients with tubulo-interstitial kidney disease) (Table 2).
About 86% of the primary cilia in the healthy control
samples and 78% in the three patients with tubulo-intersitial
kidney disease were UMOD-positive, while only 31% of
cilia in UMOD patients were UMOD-positive (13 in two
UMOD patients compared with 152 in the four healthy
control samples and 119 in patients with tubulo-intersitial
kidney disease) (Table 2). In patients with UMOD mutations,
some primary cilia may still be found and appear morphologi-
cally normal, yet the total number of cilia and UMOD-positive
Figure 1. Analysis of the UMOD mouse antibody by western blot. Character-
ization of the UMOD mouse antibody. Cell lysates of IMCD3 cells were ana-
lyzed using 8% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE) and probed with the mouse antibody for UMOD. The left
panel shows the Ponceau staining of the western blot, demonstrating that
similar protein concentrations were analyzed. The right blot demonstrates
UMOD expression. The first and second lanes show cell lysates of IMCD3
cells, grown for 1 (1w) and 2 weeks (2w), respectively. In the very right
lane, purified UMOD (U) was loaded as positive control. The molecular
weight is shown at the left side in kilodaltons. The 2-week-old IMCD3 cell
lysate and the urine UMOD show the expected size of 80 kDa for UMOD.
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cilia seems to be significantly lower than in the control
samples.
Analysis of IMCD3 cell cultures for ciliary expression
of UMOD by immunofluorescence
IMCD3 cells were grown on coverslips and maintained at con-
fluence for 5 days before fixation in order to ensure maximal
ciliary growth. Cells were then co-stained with antibodies
directed against UMOD (Fig. 3A and D) and the ciliary
marker acetylated tubulin (Fig. 3B and E). Images taken at
lower magnification reveal that almost every cell expresses a
single cilium at that time point. Colocalization of acetylated
tubulin and UMOD was seen at the base and along the entire
length of the cilium (Fig. 3C and F), indicating UMOD
expression in the ciliary axoneme in IMCD3 cells. Higher mag-
nification images show a punctate staining pattern (Fig. 3C′ and
F′). These findings were confirmed by independent polyclonal
antibodies against UMOD raised in goat (Fig. 3D–F and F′)
and rabbit (data not shown). Colocalization of UMOD
(Fig. 3G) and g-tubulin (Fig. 3H) indicated UMOD expression
in the basal bodies (Fig. 3I and I′). All negative controls, omit-
ting primary antibodies and using secondary antibodies alone
remained unstained (data not shown).
Analyzing UMOD expression in cilia by electron
microscopy
In order to verify ciliary UMOD expression in IMCD3 cells,
we performed immunogold labeling and electron microscopy
(EM). Prior studies with EM have demonstrated impaired traf-
ficking and retention of mutant UMOD in the ER (13). In post-
confluent IMCD3 cells, UMOD was detected by immunogold
labeling at the primary cilium, at the plasma membrane and in
the ER (Fig. 4A). To prove further the point that our antibody
is specific and is able to label UMOD inside the cells, we
employed HeLa cells transfected with the C150S UMOD
mutant. This mutant accumulates mainly within the ER,
while it is almost absent at the plasma membrane (13). EM
pictures clearly show specific labeling of the ER and nuclear
Figure 2. Ciliary UMOD expression in human renal biopsies. Renal samples from a human healthy control individual and two patients (K11 and F5) with UMOD
mutations were stained for UMOD (A,C,E) and acetylated tubulin (B,D,F). In the healthy individuum and patient K11, hair-like structures were identified pro-
truding into the tubular lumen of a TAL (arrows), indicating a UMOD stained cilium (A,C). Co-staining for acetylated tubulin detected exactly the same struc-
tures confirming ciliary expression of UMOD (B,D). In patient F5, a significant decrease of UMOD-positive tubulus was found. The staining pattern was
irregular and the UMOD signal was not as uniformly distributed as in the control (E). There was a significant decrease in the total number of cilia detected
by acetylated tubulin staining (F). In addition, the less abundant cilia were never co-stained for UMOD as indicated exemplarily by an arrow in (E) and (F).
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envelop in transfected cells, while no labeling can be seen
inside untransfected cells (Fig. 4B). This suggests that the anti-
body specifically labels intracellular structures when UMOD
is present.
Mutant UMOD transfected IMCD3 cells show no UMOD
ciliary expression
Examination of the renal tissue from two patients with UMOD
mutations (K11 and F5) had revealed firstly a decrease in the
total number of cilia and secondly a reduction in the number of
UMOD-positive cilia when compared with controls (Fig. 2,
Supplementary Material, Fig. S2, Table 2). In order to
support our findings in human kidney biopsies, we transfected
IMCD3 cells using previously described UMOD constructs,
including two UMOD missense mutations (C150S, T225K)
(13). We used an antibody directed against green fluorescent
protein (GFP) to visualize exclusively transgenic UMOD
protein (Fig. 5A). We found that in IMCD3 cells, the wild-
type UMOD was trafficked normally and a typical cell
surface staining was observed (Fig. 5A). In contrast, the
UMOD mutation interferes with normal protein trafficking
and intracellular protein aggregates were detected frequently
(Fig. 5B). By co-staining with antibodies directed against
GFP (Fig. 5C and D) and acetylated tubulin (Fig. 5E and F),
we could show that transfected wild-type UMOD colocalizes
partially with cilia (Fig. 5G), whereas mutant UMOD shows
no ciliary expression (Fig. 5H). We were able to confirm our
findings by using another UMOD mutation construct
(T225K). The T225K UMOD mutation is known to result in
a milder phenotype as the C150S UMOD mutation. The
T225K mutation results in a better transport of UMOD
protein to the plasma membrane compared with the C150S
UMOD mutation (13). This is underlined by a more even
and regular UMOD plasma membrane staining in the T225K
UMOD transfected cells (Supplementary Material, Fig. S3).
However, ciliary staining for UMOD is still absent (Sup-
plementary Material, Fig. S3). This study confirms the
ciliary expression and localization of UMOD using a second
independent antibody for detection. Interestingly, expression
of the C150S and T225K mutated UMOD resulted in an
absence of UMOD ciliary expression, but did not necessarily
lead to a loss of cilia (Fig. 5D, F and H).
Analysis of colocalization of UMOD, nephrocystin-1 and
KIF3 in IMCD3 cells by immunofluorescence
In order to investigate whether UMOD colocalizes with other
cystoproteins, IMCD3 cells were co-stained with antibodies
directed against UMOD (Fig. 6A and D), nephrocystin-1
(Fig. 6B) and kinesin family member 3A (KIF3A) (Fig. 6E),
respectively. Immunofluorescence showed a partial colocaliza-
tion of UMOD with both nephrocystin-1 and KIF3A in cilia
(Fig. 6C and F).
Analyzing UMOD expression in dividing IMCD3 cells
As nephrocystin-4 (alias nephroretinin), inversin (alias
nephrocystin-2), nephrocystin-6 and RPGRIP1L (alias
nephrocystin-8) were all shown to be expressed in the
mitotic spindle poles (44–46), we were interested if UMOD
would also be expressed at this position. Figure 7 shows stain-
ing of IMCD3 cells with polyclonal rabbit antibodies for
UMOD (Fig. 7A) and acetylated tubulin (Fig. 7B). In
mitotic cells, UMOD and acetylated tubulin colocalized at
the spindle poles (Fig. 7C and C′) in a similar manner to
nephrocystin-4 (nephroretinin) and inversin (44,47).
DISCUSSION
In patients with clinical evidence of UAKD, we found a total
of seven new UMOD mutations in 11 individuals and con-
firmed three previously published mutations in another three
individuals (Table 1). In our patient group, a cysteine
residue was involved in six out of seven of the new mutations
and in two out of the three known mutations. Cysteine is
crucial for the formation of disulfide bridges and thus influ-
ences protein conformation. All new mutations were found
in individuals with an autosomal-dominant pattern of renal
disease. One patient (F7) had a more complex phenotype
including mental retardation and hearing impairment. Five of
the 11 patients had gout or hyperuricemia. All of our
mutations are either missense mutations or deletions and
occur in exons 4 or 5.
Patient F5’s kidney biopsy appears more severely affected
by the disease with significantly more tubular atrophy than
patient K11. In comparison with patient K11, patient F5 had
an earlier age of onset (36 versus 46 years), a lower GFR
(37.5 versus 58 ml/min/1.73 m2) and a higher serum creatinine
(2.5 versus 1.5 mg/dl). Patient K11 had a severe clinical
course and was started on peritoneal dialysis at 52 years.
For patient F5, we do not have a significant follow-up
period yet. Currently, patient F5 has chronic kidney disease
stage 3 and no dialysis requirement.
By demonstrating an aberration in ciliary expression of
UMOD, we suggest a novel pathophysiological mechanism
for the etiology of MCKD2, FJHN and GCKD, by describing
abberant ciliary expression of UMOD in patients with UMOD
mutations. MCKD has previously been described to be part of
the disease complex called ‘nephronophthisis–MCKD
complex’ (4,5), given the fact that renal biopsies of patients
with MCKD or nephronophthisis are indistinguishable.
UMOD co-expression with nephrocystin-1 in the mitotic
spindle and the decreased number of UMOD-positive cilia in
Table 2. Comparison of the numbers of cilia and UMOD-positive cilia in renal
biopsies of four control individuals, two UMOD patients and three patients with
other tubulo-interstitial kidney diseases (TIKD). Twenty tubules were analyzed
in each individual
Sample UMOD-positive cilia
(%)
P-valuea No. of tubules
analyzed
Control group
(n ¼ 4)
152/176 (86) 80
UMOD patients
(n ¼ 2)
13/41 (31) 0.0028 40
TIKD patients
(n ¼ 3)
119/152 (78) 0.565 60
aFisher exact test determined two-tailed P-value.
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the kidney biopsies of UMOD patients suggests a specific
function of UMOD in cilia. We showed that the reduced
ciliary UMOD staining is specific for UMOD mutations and
cannot be found in kidney biopsies of patients with other
tubulo-interstitial kidney disorders (Supplementary Material,
Fig. S2). Using transfection of wild-type and mutant UMOD
constructs into IMCD3 cells, we reproduce the mislocalization
defect for mutant UMOD in IMCD3 cells. The level of
expression was similar for both constructs but the subcellular
localization was clearly different (Fig. 5). We then analyzed
the presence of cilia in transfected cells and could show that
overexpressed wild-type UMOD could be detected in cilia.
Expression of mutant UMOD showed absence of UMOD
expression in primary cilia but did not result in a loss of
cilia excluding a dominant-negative effect on cilia formation.
Our findings suggest that there may be a common pathome-
chanism between these seperate genetic diseases, as their
gene products colocalize to the same subcellular structures
and suggest an involvement of UMOD in the nephrocystin
multiprotein complex. There is significant overlap in the regu-
lation and function of nephrocystins, polycystins, polyductin
and UMOD, which supports our hypothesis. Firstly, a centro-
somal localization was shown for nephrocystin-4,
nephrocystin-6, RPGRIP1L/nephrocystin-8 and NEK8/
nephrocystin-9 (44–46,48), while ciliary and basal body local-
ization was demonstrated for nephrocystin-4 and RPGRIP1L/
nephrocystin-8 (44,46). This corresponds to the same location
where we identified UMOD by colocalization with g-tubulin.
Pyk2 and p130Cas have been shown to be part of the
nephrocystin-1/nephrocystin-4 multiprotein complexes
(44,49). A similar multiprotein complex was described for
polycystin-1 and -2 with KIF3B (50). Even though colocaliza-
tion does not necessarily mean that the proteins are active in
the same pathway, we here show colocalization of UMOD
with nephrocystin-1 and KIF3A, suggesting that UMOD
may take part in such a multiprotein complex.
Secondly, it is interesting, that UMOD is also regulated by
HNF1B, a transcription factor which also activates the nephro-
cystins and polycystins (43).
Moreover, sequence analysis has revealed ciliary localiz-
ation sequences in polycystin-2 and G-protein-coupled recep-
tors (51,52). A very short ciliary localization sequence shown
for mouse somatostatin receptor 2 and 5 is shared by UMOD.
This ciliary localization sequence encompasses the amino
acids IRVG from position 448 to 451 and is located at the
beginning of exon 8.
It is intriguing to speculate whether a secreted protein can
play a role in planar orientation. Similar to UMOD, polyduc-
tin, which if altered causes ARPKD, is expressed in the
primary cilium and is also secreted (53,54). The shed polyduc-
tin ectodomain and a concomitant C-terminal product, which
is localized to the nucleus, may regulate the planar orientation
of developing renal tubules in a paracrine fashion (53,54). This
could imply that ciliary localized and secreted forms of pro-
teins could have different functions.
Furthermore, ciliary function includes mechanosensation of
urinary flow (55). It is speculated that the primary cilia sense
the urine flow and thus provide vectorial information for orien-
tated cell division (56). It is tempting to speculate that the
protein expression in the TAL may be regulated by a
mechano- or osmosensor, such as the primary cilium. Cilia
are also involved in the canonical Wnt signaling pathway
Figure 3. Immunofluorescence analysis of IMCD3 cell cultures for ciliary expression of UMOD. IMCD3 cells were stained with antibodies directed against
UMOD (A,D,G) acetylated tubulin (B,E) and gamma tubulin (H). Co-staining of UMOD using two independent antibodies raised in mouse (A) and goat
(D) with acetylated tubulin revealed an UMOD expression along the cilium (C,F). Higher magnifications show a punctate and not completely overlapping stain-
ing pattern (C′,F′). Co-staining of UMOD (G) and gamma tubulin (H) indicates the presence of UMOD also at the base of the cilium (I,I′). Merging these images
shows colocalization of UMOD and g-tubulin indicating expression of UMOD in basal bodies. All negative controls remained negative (data not shown). The
scale bar represents 10 mm in (C, F and I) and 5 mm in (C′, F′ and I′), respectively.
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(57). KIF3A has been shown to regulate the Wnt signaling
pathway (58). The colocalization of KIF3A and UMOD
could suggest that UMOD may be involved in the Wnt regu-
lation also. Finally, cilia regulate cell cycle, cell proliferation
and planar cell polarity. Nephrocystin-4 (44) and UMOD were
also shown to be expressed in the mitotic spindle and defective
proteins could cause either problems concerning the angle of
the mitotic spindle or could cause dysfunction of the mitotic
spindle, thus resulting in cyst formation.
Future studies will be required to address the specific role of
UMOD in the context of the cilium.
The phenotypic variability in patients (MCKD2, FJHN,
GCKD) with the same UMOD mutation and the previously
known significant intrafamiliar differences in the phenotype
have raised questions about additional contributing factors.
We think that the conditional Kif3a knock-out mouse model
(59) may improve our understanding with regard to phenotype
variability. Adult conditional Kif3a knock-out mice did not
develop cysts rapidly, despite a loss of primary cilia.
However, acute kidney injury exacerbated cystic kidney
disease underlining that Kif3a in primary cilia are required
for the maintenance of planar cell polarity in the kidney
(59). Only an additional trigger-like induction of acute renal
injury, which resulted in increased cell proliferation, caused
the development of renal cysts in mice (59).
Treatment of UMOD patients has been very challenging with
contradictory reports about successful treatment with allopuri-
nol and benzbromarone (7). Recently, inhibition of URAT1
by losartan was published (60), providing us with a new alterna-
tive medication for the treatment of hyperuricemia, which also
addresses hypertension and proteinuria in UMOD patients.
Here, we present evidence that UMOD is ciliary and centro-
somal expressed, implicating UMOD as a cystoprotein. We
show that a decreased ciliary UMOD expression occurs fol-
lowing C150S, T225K (both in cell culture), W230R and
C248W (both in kidney biopsies) UMOD mutations and may
provide a pathophysiological mechanism contributing to this
disease. We link UMOD to the ciliary network of proteins
by colocalization with nephrocystin-1 and KIF3A. It is
likely that UMOD is part of a multiprotein complex and
takes part in the maintenance of cilia.
MATERIALS AND METHODS
Patients
We ascertained blood from 54 individuals from 44 different
families who had a phenotype consistent with UAKD. Families
are from Germany, Switzerland, the Netherlands, the UK and
USA. Age at diagnosis, age at onset of ESRD, hyperuricemia,
imaging data and biopsy results were reviewed if available.
Diagnostic criteria were normal or small-sized kidneys with
occasional small cortico-medullary cysts and renal insuffi-
ciency. At least one of the optional criteria as hypertension, a
family history of renal disease, reduced fractional urinary
excretion of uric acid or hyperuricemia was required. Hyperur-
icemia was defined as serum uric acid concentration .1 stan-
dard deviations higher than the normal values for age and
gender (61). Renal biopsies from the UMOD patients were
obtained where available. The kidney samples used as a
control for UMOD expression were obtained from healthy
poles of kidneys from nephrectomy specimens as part of the
treatment for renal tumors. Additional control samples from
patients with other tubulo-interstitial kidney disease were
obtained from one patient with primary hyperoxaluria and
two patients with interstitial nephritis. Samples were routinely
fixed in 4% formaldehyde and embedded in paraffin. The
study was approved by the institutional review board of the Uni-
versity of Cologne, Medical School. All participating family
members provided informed consent.
Mutational analysis of the UMOD gene
Mutational analysis was performed by exon PCR of the
UMOD gene. Primer sequences were used as described by
Figure 4. Analyzing UMOD expression in cilia by electron microscopy. (A)
Endogenous ciliary UMOD expression in post-confluent IMCD3 cells was
studied by electron microscopy. UMOD was detected by goldstaining in the
ER, plasma membrane and at the cilium (arrows). (B) Positive and negative
controls underlining the specifity of the immunogold UMOD antibody
study. HeLa cells were transfected with the C150S UMOD mutant DNA.
The C150S UMOD protein resides mainly within the ER (13). The upper
and lower cells represent transfected cells (asterisks) with intense gold label-
ing along the ER membranes and nuclear envelop (arrows), while ER mem-
branes and nuclear envelop (arrowheads) in the untransfected cell (in the
middle) remain mostly devoid of gold particles. Untransfected HeLa cells
do not express UMOD. Few randomly distributed particles that are visible
inside untransfected cells were interpreted as background. ER, endoplasmic
reticulum; N, nucleus; C, cilia.
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Figure 5. Overexpression of wild-type and mutant UMOD in IMCD3 cells. IMCD3 cells were transfected with wild-type (A,C,E,G) or C150S mutant
UMOD–EGFP fusion constructs (B,D,F,H) and processed for immunofluorescence staining. Using an antibody directed against GFP, wild-type UMOD
was mainly localized to the cell surface (A), while C150S mutant UMOD was detected mainly intracellularly in larger aggregates (B). A co-staining with
antibodies directed against GFP and acetylated tubulin revealed ciliary expression for wild-type UMOD. Ciliary structures stained with both antibodies
are indicated by arrows (C,E,G). In contrast, transfection with mutant UMOD did not result in ciliary UMOD localization (D,H). However, mutant
UMOD-expressing cells still display cilia as indicated by arrows (F). A merge of the boxed areas in Figure 5C–F is shown in higher magnification
(G,H). The scale bar represents 10 mm.
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Wolf et al. (11). PCR products were purified using the Marli-
gen Rapid PCR Purification System. Purified PCR products
were sequenced, using a Genetic Analyzer 3700 (Applied Bio-
systems) and resulting sequences were evaluated with the
SequencherTM software.
Cell culture and transfection
mIMCD3 cells were obtained from the American Type
Culture Collection (www.atcc.org).
IMCD3 cells were maintained in DMEM/F12 media (Invi-
trogen) supplemented with 10% fetal calf serum, 2.5 mM
L-glutamine, 15 mM HEPES, 0.5 mM sodium pyruvate, 1.2 g/l
sodium bicarbonate. IMCD3 cells were transfected with
Fugene (Roche) according to the manufacturer’s instructions.
The GFP-tagged wild-type and missense mutant (C150S,
T225K) constructs have been described in detail (13).
SDS-PAGE and immunoblotting
Cell extracts were prepared by directly adding 2× SDS
sample buffer (50 mM Tris–HCl, pH 6.8, 2% (w/v) SDS,
20% glycerol and 0.025% (w/v) bromphenol blue) to
the cell layer. Samples were reduced (4% 2-mercaptoethanol,
followed by 7 min heating at 958C) and separated using 8%
SDS–PAGE and transferred to nitrocellulose. After blocking,
membranes were incubated either 1 h at room temperature
(RT) or overnight at 48C with primary antibodies (mouse
monoclonal antibody against uromodulin, 1:500 dilution,
Biozol, Eching, Germany), washed, incubated for 1 h at RT
with a peroxidase-labeled antibody (Dako, Glostrup,
Denmark), washed again and visualized with enhanced chemi-
luminescence. Specificity of the immunoblot was determined
by co-migration with purified human uromodulin (Human
Tamm Horsfall Glycoprotein, SCIPAC Ltd., Sittingbourne,
UK) and diluted urine. In blocking experiments, the primary
antibody directed against UMOD was preincubated overnight
at 48C with UMOD protein purified from urine.
Immunofluorescence
For immunofluorescence stainings, 20 000 cells were grown
on glass chamber slides (Nalge Nunc Int., Rochester, NY,
USA) for the indicated time after having reached confluency.
Cells were fixed with 100% methanol for 10 min at 2208C,
washed, blocked with 1% normal goat serum or 5% fetal calf
serum and incubated with primary antibodies either for 2 h at
RT or overnight at 48C: mouse anti-human Tamm-Horsfall
Figure 6. Colocalization of UMOD with nephrocystin-1 and KIF3A in cilia. IMCD3 cells were stained with antibodies directed against UMOD (A,D)
nephrocystin-1 (B) and KIF3A (E). A merge of these stainings (C,F) demonstrate partial colocalization of UMOD with nephrocystin-1 and KIF3A. The
scale bar in (C) and (F) represents 5 mm.
Figure 7. Detection of UMOD expression in the mitotic spindle poles. IMCD3 cell cultures were co-stained with antibodies directed against UMOD (A) and
acetylated tubulin (B). In a mitotic cell, both signals colocalize in the spindle poles indicated by arrows (C). Higher magnification (C′). The scale bar in (C) and
(C′) represent 10 and 5 mm, respectively.
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protein (THP) monoclonal IgG2b (Biozol, Eching, Germany;
dilution 1:500), goat anti-human THP polyclonal IgG
(MP Biomedicals, Illkirch, France; dilution 1:100) or rabbit
anti-human THP polyclonal IgG (Biotrend, Cologne,
Germany; dilution 1:500) for UMOD detection; rabbit anti-
nephrocystin-1 (NPHP1) polyclonal IgG (Biozol, Eching,
Germany; dilution 1:100) and rabbit anti-KIF3A polyclonal
IgG (Sigma, Saint Louis, USA; dilution 1:500) for spindle
and plasma membrane localization; mouse anti-acetylated
tubulin monoclonal IgG (Sigma, St Louis, USA; dilution
1:2000) and rabbit anti-acetylated tubulin polyclonal IgG
(Biomol GmbH, Hamburg, Germany; dilution 1:500) for
cilium detection; mouse anti-g-tubulin monoclonal IgG
(Sigma; dilution 1:300) for centrosome localization and
anti-GFP rabbit polyclonal (Abcam, Cambridge, UK; dilution
1:500). For detection, fluorescence-labeled antibodies Alexa
Fluor 488 goat anti-rabbit IgG, Alexa Fluor 488 donkey anti-
goat IgG, Cy3 goat anti-mouse IgG, Cy3 donkey anti-rabbit
IgG (Jackson Molecular Probes; dilution 1:1000) were used.
For nuclear counterstaining, bisbenzimide (Sigma, Germany)
was added to the cells for 3 min at a final concentration of
0.05 mg/ml. Slides were mounted in fluorescence mounting
medium (DakoCytomation, Glostrup, Denmark) and analyzed
by fluorescence (Axiophot, Zeiss) or confocal microscopy
(Leica DMIRE 2). The blocking experiment was performed
as described above. Paraffin-embedded tissue sections were
processed using standard protocols and stained as described
above.
Immuno-electron microscopy analysis
Post-confluent IMCD3 cells and transfected HeLa cells were
fixed with a mixture of 4% paraformaldehyde and 0.05% glu-
taraldehyde 6–8 h after transfection, labelled with goat poly-
clonal primary antibody against uromodulin (ICN
biomedicals) using the gold-enhance protocol, embedded in
Epon-812 and cut as described previously (62). EM images
were acquired from thin sections under a Philips Tecnai-12
electron microscope (Philips, Eindhoven, The Netherlands)
using an ULTRA VIEW CCD digital camera.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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